Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance

Medicine and Dentistry

• Rituximab 100%
• Patient 100%
• Progressive Multifocal Leukoencephalopathy 82%
• Bendamustine 52%
• Follicular Lymphoma 35%
• JC Virus 29%
• Therapeutic Procedure 23%
• Diagnosis 17%
• Follow up 11%
• Diseases 11%
• Human Immunodeficiency Virus 11%
• Neoplasm 11%
• Lymphocyte 11%
• Symptom 11%
• Incidence 11%
• Cells 11%
• Inpatient 11%
• Cell Count 11%
• Blood 11%
• Complication 5%
• Cause of Death 5%
• Immunophenotyping 5%
• Lymphoma 5%
• Immunosuppressive Treatment 5%
• Population 5%
• Age 5%
• Virus Infection 5%
• Sequela 5%
• Monoclonal Antibody 5%
• Drug 5%
• Induction Chemotherapy 5%
• Chemotherapeutic Agent 5%
• T Cell Activation 5%
• Maintenance Therapy 5%
• Gastrointestinal Bleeding 5%
• Effector Cell 5%
• Lymphocytopenia 5%
• Drive 5%
• Sepinostat 5%
• B Cell 5%
• Analysis 5%
• Experience 5%
• Observation 5%
• Consensus 5%
• Human 5%
• Neurology 5%
• Male 5%
• Female 5%
• Cytotoxic T-Cell 5%
• Chronic Lymphocytic Leukemia 5%
• Organ 5%

Neuroscience

• Rituximab 100%
• Progressive Multifocal Leukoencephalopathy 82%
• Bendamustine 52%
• Lymphoma 41%
• JC Virus 23%
• Brain 23%
• CD4 17%
• HIV 11%
• Cell Activation 5%
• Serology 5%
• B Cell 5%
• Chemotherapy 5%
• Immunosuppression 5%
• CD8 5%
• Monoclonal Antibody 5%
• CD19 5%
• Immunophenotyping 5%
• Lymphocytopenia 5%

Biochemistry, Genetics and Molecular Biology

• Rituximab 100%
• Bendamustine 52%
• JC Virus 29%
• CD4 17%
• Time 17%
• T Cell 11%
• Human Immunodeficiency Virus 11%
• Tumor Volume 11%
• CD4 Lymphocyte Count 11%
• Incidence 11%
• Polymerase Chain Reaction 11%
• Lymphocyte Count 11%
• Human 5%
• Serology 5%
• Monoclonal Antibody 5%
• B Cell 5%
• Cell Activation 5%
• CD8 5%
• Population 5%
• Age 5%
• Experience 5%
• Reduction (Chemistry) 5%
• Drive 5%
• Consensus 5%
• CD19 5%
• Immunophenotyping 5%